Abstract
This study supports the use of intraoperative radiation therapy (IORT) with a 50 kV X-ray source in treating resectable pancreatic cancer (RPC). The interim results indicate that IORT using a low-energy X-ray source is well-tolerated and feasible. Additionally, preoperative levels of D-dimer, CEA, and CA19-9 may serve as critical biomarkers to identify patient profiles that potentially benefit most from this targeted treatment.
Introduction
Pancreatic cancer remains one of the most challenging malignancies to treat, with a 5-year survival rate often below 13%. Even for patients with resectable tumors, local recurrence rates are high, ranging from 50% to 80%. Intraoperative radiation therapy (IORT) aims to mitigate this by delivering a high dose of radiation directly to the tumor bed immediately following surgical resection. While traditional IORT requires complex logistics and shielded rooms for electron beams, this study evaluates a miniaturized 50 kV X-ray source that can be safely integrated into a standard operating room.
Methods
This prospective phase II clinical trial enrolled 35 patients with resectable pancreatic cancer (RPC) located in the body or tail of the pancreas. Following radical distal pancreatectomy, a mobile 50 kV X-ray source (Intrabeam 600) delivered 10–20 Gy of radiation to the surgical site. The procedure was guided by intraoperative cone beam CT (CBCT) for precise 3D treatment planning. The primary endpoint was Time to Treatment Failure (TTF), with secondary endpoints including Overall Survival (OS) and safety.
Key Results and Local Control
The interim analysis showed a median Overall Survival (OS) of 22.2 months and a median Time to Treatment Failure (TTF) of 11.67 months. Notably, the local recurrence rate was only 20%, a significant improvement over historical norms of 50-80% for surgery alone.
In terms of safety, the treatment was generally well-tolerated. While pancreatic fistula was the most common complication (reported in 94.2% of cases), the vast majority were mild (Grade A) and did not significantly increase standard surgical risks.
Prognostic Biomarkers
The study identified a "biomarker trifecta"—preoperative levels of Carcinoembryonic antigen (CEA), D-dimer, and CA19-9—as independent prognostic factors. High levels of D-dimer and CEA were strongly correlated with shorter survival and faster treatment failure. Conversely, patients with low D-dimer and normal CA19-9 levels experienced significantly prolonged survival when receiving tailored IORT doses.
Discussion and Limitations
These interim results suggest that low-energy X-ray IORT is a practical and effective addition to the surgical management of pancreatic cancer. By lowering logistical barriers, this technology allows for more widespread adoption of image-guided radiation in the operating room. However, the study is limited by its small sample size (n=35) and single-arm design. Future randomized controlled trials with larger cohorts and standardized adjuvant chemotherapy protocols are necessary to confirm these survival benefits and refine patient selection based on biological profiles.
Summary updated